J&K High Court Summons JKMSCL Managing Director Over Critical Haemophilia Drug Shortage

The High Court of Jammu & Kashmir and Ladakh has taken a stern stance against the acute shortage of life-saving anti-haemophilia drugs at government medical colleges, ordering the personal appearance of the Managing Director of the Jammu & Kashmir Medical Supplies Corporation Limited (JKMSCL) to explain the failure to supply essential medications. The Bench, comprising Acting Chief Justice Sanjeev Kumar and Justice Mohd Yousuf Wani, expressed strong displeasure over what it termed "slackness" on the part of the state-owned procurement body, which has left hundreds of haemophilia patients without critical clotting factors.

The order came during the hearing of a Public Interest Litigation (PIL) filed by the Hemophilia Society of Kashmir, which has been persistently highlighting the irregular supply of Factor-VIII and Emicizumab—medicines essential for preventing uncontrolled bleeding, permanent disability, and life-threatening complications in haemophilia patients. The court noted that despite repeated reminders from the Government Medical Colleges (GMCs) in Srinagar and Jammu, JKMSCL failed to respond, resulting in a dire shortage that has adversely affected nearly 300 patients at GMC Srinagar alone.

Court's Observations and Directions

In its order, the High Court observed that the affidavit filed by the Principal of GMC Srinagar made it clear that both medical colleges were "facing shortage rather non-availability of the aforementioned medicines and are in dire need thereof." The Bench further remarked that it appeared to be "because of the slackness on the part of respondent No. 3, the Jammu and Kashmir Medical Supplies Corporation Limited that the matter has not been addressed and the patients are suffering."

Dissatisfied with the compliance affidavit submitted by the respondents, the court directed the Managing Director of JKMSCL to personally appear on the next date of hearing and file an advance affidavit detailing how the corporation had responded to the needs projected by the two GMCs. The court listed the matter for further hearing on September 7, 2026.

Background of the PIL

The Hemophilia Society of Kashmir had initially approached the court raising the issue of continual shortages and irregular supply of clotting factors at government health facilities, particularly the Day Care Centre at SMHS Hospital, Srinagar. The petition contended that interruptions in the supply of these medicines expose haemophilia patients to uncontrolled bleeding, permanent disability, and life-threatening complications. On July 13, 2026, the court had directed the Principal of GMC Srinagar to file an affidavit within two weeks detailing steps taken to restore availability of the drugs. The court also ordered JKMSCL to respond forthwith to any requisition placed.

During the July hearing, Senior Advocate Iman Abdul Muizz, representing the petitioner, informed the court that GMC Srinagar was facing an acute shortage of Factor-VIII and Emicizumab, affecting nearly 300 patients. The court had then directed the Principal to ensure that the deficiency is addressed immediately so that no patient suffers for want of these medicines.

Legal and Public Health Implications

The case underscores the judiciary's role in enforcing the right to health under Article 21 of the Constitution, especially in the context of government procurement and supply chain failures. By summoning the Managing Director of JKMSCL personally, the High Court has signaled that administrative negligence in the supply of life-saving drugs will not be tolerated. Legal experts note that this approach follows a growing trend of courts using contempt-like powers to ensure accountability in public health emergencies.

The shortage of haemophilia drugs is particularly critical because patients require regular prophylactic infusions to prevent spontaneous bleeding episodes. Any interruption can lead to irreversible joint damage, internal hemorrhages, and increased mortality. The court's intervention may prompt other state procurement agencies to reassess their inventory management and responsiveness to medical institutions.

Impact on Legal Practice and Government Procurement

For legal professionals handling public interest litigation or healthcare-related cases, this order illustrates the effectiveness of judicial oversight in compelling state agencies to perform their duties. The court's insistence on personal presence and advance affidavit is a procedural tool that can be replicated in similar cases of regulatory or administrative failure.

Moreover, the case highlights the importance of maintaining documentary evidence of requisitions and communications with procurement bodies. The court relied on the affidavits from GMC Srinagar to establish non-compliance. This serves as a reminder for public health litigants to diligently preserve such records.

The outcome of the September 7 hearing will be closely watched. If the Managing Director fails to provide a satisfactory explanation, the court may consider further sanctions, including possible contempt proceedings or directions for interim procurement. The case also raises questions about the efficiency of centralized medical supplies corporations in states with challenging terrain and multiple healthcare facilities.

Conclusion

The J&K High Court's strong action in summoning the JKMSCL Managing Director sends a clear message that the non-availability of life-saving drugs due to bureaucratic inertia is unacceptable. With the next hearing scheduled for early September, the court has put the onus on the state procurement agency to urgently restore supplies and ensure that no haemophilia patient suffers avoidable harm. The legal community will be watching how this case influences future judicial responses to medicine shortages across India.